IFX-1 + Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Systemic Inflammatory Response Syndrome
Conditions
Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac
Trial Timeline
May 1, 2016 → Jan 1, 2017
NCT ID
NCT02866825About IFX-1 + Placebo
IFX-1 + Placebo is a phase 2 stage product being developed by InflaRx for Systemic Inflammatory Response Syndrome. The current trial status is completed. This product is registered under clinical trial identifier NCT02866825. Target conditions include Systemic Inflammatory Response Syndrome, C.Surgical Procedure; Cardiac.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03487276 | Phase 2 | Completed |
| NCT02866825 | Phase 2 | Completed |
Competing Products
20 competing products in Systemic Inflammatory Response Syndrome
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tabalumab Auto-Injector + Tabalumab Prefilled Syringe | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| MRA(Tocilizumab) + placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| MRA(Tocilizumab) | Chugai Pharmaceutical | Phase 3 | 77 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 1 | 33 |
| Parenteral micafungin application + Other parenteral antifungal drugs | Astellas Pharma | Pre-clinical | 23 |
| Micafungin | Astellas Pharma | Phase 2 | 52 |
| E6742 | Eisai | Phase 1/2 | 41 |
| KHK4827 | Kyowa Kirin | Phase 1 | 33 |
| KHK4827 + Placebo | Kyowa Kirin | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Cyclophosphamide | Eli Lilly | Approved | 85 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 33 |
Other Products from InflaRx
vilobelimab + PlaceboPhase 3
69
IFX-1 + BSC + BSC + IFX-1 + SOC + Placebo + SOCPhase 2/3
57
Cohort A: vilobelimab + Cohort A: placebo + Cohort B: paridiprubart + Cohort B: placebo + Cohort C: bevacizumab + Cohort C: placeboPhase 2
44
IFX-1 + Placebo-IFX-1 + Glucocorticoid (GC) + Placebo-Glucocorticoid (Placebo-GC)Phase 2
44
Cohort C: bevacizumab + Cohort C: placeboPhase 2
44